ALGEN.PA
genOway Société anonyme [ALGEN.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALGEN.PA Stock Summary
Top ALGEN.PA Correlated Resources
ALGEN.PA
Top 10 Correlated ETFs
ALGEN.PA
Top 10 Correlated Stocks
ALGEN.PA
ALGEN.PA Financial details
Company Rating
Buy
Market Cap
33.27M
Income
-634.41K
Revenue
9.79M
Book val./share
1.17
Cash/share
0.09
Dividend
-
Dividend %
-
Employees
128
Optionable
No
Shortable
Yes
Earnings
-
P/E
-80.6
Forward P/E
-
PEG
106.85
P/S
2.41
P/B
1.58
P/C
43.33
P/FCF
-33.34
Quick Ratio
0.81
Current Ratio
2.43
Debt / Equity
1.82
LT Debt / Equity
0.56
-
-
EPS (TTM)
-0.11
EPS next Y
-
EPS next Q
-
EPS this Y
-91.25%
EPS next Y
-
EPS next 5Y
-176.89%
EPS last 5Y
NAN%
Revenue last 5Y
7.28%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
33.33%
Inst Own
-
Inst Trans
-
ROA
-2%
ROE
-5%
ROC
-0.16%
Gross Margin
43%
Oper. Margin
-40%
Profit Margin
-6%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.64-4.72
52W High
-2.5%
52W Low
+95%
RSI
49
Rel Volume
0.91
Avg Volume
7.07K
Volume
6.42K
Perf Week
-6.7%
Perf Month
7.14%
Perf Quarter
22.64%
Perf Half Y
15.56%
-
-
-
-
Beta
0.508301
-
-
Volatility
0.12%, 0.16%
Prev Close
-2.74%
Price
3.9
Change
1.04%
ALGEN.PA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2019-12-31
| Metric | History | 2015-12-31 | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.35 | 1.52 | 1.66 | 1.85 | 1.61 | |
| Net income per share | 0.01 | 0.1 | 0.32 | 0.1 | -0.18 | |
| Operating cash flow per share | 0.14 | -0.15 | 0.42 | 0.37 | -0.37 | |
| Free cash flow per share | 0.12 | -0.2 | -0.45 | -0.29 | -0.57 | |
| Cash per share | 0.63 | 0.44 | 0.66 | 0.52 | 0.19 | |
| Book value per share | 0.78 | 0.88 | 1.21 | 1.35 | 1.17 | |
| Tangible book value per share | 0.79 | 0.75 | 2.78 | 2.9 | 2.73 | |
| Share holders equity per share | 0.78 | 0.88 | 1.21 | 1.35 | 1.17 | |
| Interest debt per share | 0 | 0.02 | 0.6 | 0.71 | 0.86 | |
| Market cap | 9.63M | 12.27M | 11.91M | 13.74M | 9.96M | |
| Enterprise value | 5.87M | 9.63M | 11.71M | 15.01M | 14.14M | |
| P/E ratio | 250.95 | 21.07 | 6.17 | 24.03 | -9.61 | |
| Price to sales ratio | 1.19 | 1.35 | 1.21 | 1.27 | 1.05 | |
| POCF ratio | 11.32 | -13.6 | 4.8 | 6.35 | -4.55 | |
| PFCF ratio | 13.96 | -10.45 | -4.42 | -8.11 | -2.99 | |
| P/B Ratio | 2.06 | 2.33 | 1.66 | 1.74 | 1.45 | |
| PTB ratio | 2.06 | 2.33 | 1.66 | 1.74 | 1.45 | |
| EV to sales | 0.72 | 1.06 | 1.19 | 1.39 | 1.5 | |
| Enterprise value over EBITDA | 9.72 | 5.87 | 4.61 | 10.5 | 123.22 | |
| EV to operating cash flow | 6.9 | -10.68 | 4.72 | 6.93 | -6.46 | |
| EV to free cash flow | 8.51 | -8.21 | -4.34 | -8.86 | -4.24 | |
| Earnings yield | 0 | 0.05 | 0.16 | 0.04 | -0.1 | |
| Free cash flow yield | 0.07 | -0.1 | -0.23 | -0.12 | -0.33 | |
| Debt to equity | 0 | 0 | 1.39 | 1.5 | 1.8 | |
| Debt to assets | 0.56 | 0.55 | 0.58 | 0.6 | 0.64 | |
| Net debt to EBITDA | -6.23 | -1.6 | -0.08 | 0.89 | 36.48 | |
| Current ratio | 1.55 | 1.66 | 1.81 | 1.45 | 1.48 | |
| Interest coverage | 0 | 4.04 | -12.56 | -3.38 | 3.99 | |
| Income quality | 22.17 | -1.55 | 1.28 | 3.79 | 2.11 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.07 | 0.04 | 0.14 | 0.16 | |
| Capex to operating cash flow | -0.19 | 0.3 | -0.48 | -0.56 | 1.92 | |
| Capex to revenue | -0.02 | -0.03 | -1.91 | -2.8 | -8.27 | |
| Capex to depreciation | -0.27 | -0.28 | -0.15 | -0.27 | -1.17 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.34 | 1.39 | 2.97 | 1.72 | 2.16 | |
| ROIC | 0.08 | 0.09 | 0.17 | 0.05 | -0.08 | |
| Return on tangible assets | 0 | 0.05 | 0.12 | 0.03 | -0.06 | |
| Graham Net | -0.35 | -0.57 | -0.22 | -0.62 | -0.85 | |
| Working capital | 3.27M | 4.1M | 4.75M | 3.15M | 3.17M | |
| Tangible asset value | 0 | 4.5M | 6.58M | 5.17M | 3.7M | |
| Net current asset value | 3.15M | 3.83M | 600.12K | -1.59M | -2.54M | |
| Invested capital | 0.01 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 6.23M | 6.49M | 7.18M | |
| Average payables | 1.69M | 1.85M | 1.51M | 2.25M | 2.32M | |
| Average inventory | 793.08K | 949.9K | 506.81K | 544.47K | 610.45K | |
| Days sales outstanding | 0 | 0 | 220.95 | 219.33 | 303.53 | |
| Days payables outstanding | 89.49 | 433.52 | 164.41 | 784.82 | 1.08K | |
| Days of inventory on hand | 34.65 | 227.44 | 99.98 | 190.17 | 305.77 | |
| Receivables turnover | 0 | 0 | 1.65 | 1.66 | 1.2 | |
| Payables turnover | 4.08 | 0.84 | 2.22 | 0.47 | 0.34 | |
| Inventory turnover | 10.53 | 1.6 | 3.65 | 1.92 | 1.19 | |
| ROE | 0.01 | 0.11 | 0.27 | 0.07 | -0.15 | |
| Capex per share | -0.03 | -0.05 | -0.87 | -0.66 | -0.2 |
Quarterly Fundamentals Overview
Last date of statement is 2019-06-30 for Q2
| Metric | History | 2015-06-30 | 2016-06-30 | 2017-06-30 | 2018-06-30 | 2019-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.34 | 0.38 | 0.84 | 0.86 | 0.68 | |
| Net income per share | 0 | 0.02 | 0.27 | 0.06 | -0.18 | |
| Operating cash flow per share | 0.04 | -0.04 | 0.04 | -0.24 | -0.59 | |
| Free cash flow per share | 0.03 | -0.05 | -0.65 | -1.34 | -0.73 | |
| Cash per share | 0.49 | 0.4 | 0.4 | 0.26 | 0.09 | |
| Book value per share | 0.79 | 0.81 | 1.15 | 1.31 | 1.17 | |
| Tangible book value per share | 0.79 | 0.81 | 2.73 | 3.01 | 2.77 | |
| Share holders equity per share | 0.79 | 0.81 | 1.15 | 1.31 | 1.17 | |
| Interest debt per share | 0 | 0.01 | 0.58 | 0.78 | 0.94 | |
| Market cap | 12.51M | 9.51M | 13.33M | 9.73M | 9.14M | |
| Enterprise value | 9.59M | 7.19M | 14.57M | 12.74M | 14.23M | |
| P/E ratio | 325.76 | 16.34 | 8.33 | 30.36 | -8.74 | |
| Price to sales ratio | 6.17 | 4.19 | 2.68 | 1.98 | 2.28 | |
| POCF ratio | 58.77 | -42.2 | 51.26 | -7.12 | -2.65 | |
| PFCF ratio | 72.49 | -32.42 | -3.45 | -1.27 | -2.15 | |
| P/B Ratio | 2.65 | 1.96 | 1.94 | 1.29 | 1.33 | |
| PTB ratio | 2.65 | 1.96 | 1.94 | 1.29 | 1.33 | |
| EV to sales | 4.73 | 3.17 | 2.93 | 2.6 | 3.55 | |
| Enterprise value over EBITDA | 63.51 | 17.51 | 6.74 | 16.16 | -28.64 | |
| EV to operating cash flow | 45.06 | -31.89 | 56.03 | -9.33 | -4.12 | |
| EV to free cash flow | 55.58 | -24.5 | -3.77 | -1.66 | -3.34 | |
| Earnings yield | 0 | 0.02 | 0.12 | 0.03 | -0.11 | |
| Free cash flow yield | 0.01 | -0.03 | -0.29 | -0.79 | -0.47 | |
| Debt to equity | 0 | 0 | 1.46 | 1.45 | 1.82 | |
| Debt to assets | 0.52 | 0.56 | 0.59 | 0.59 | 0.65 | |
| Net debt to EBITDA | -19.33 | -5.66 | 0.57 | 3.82 | -10.26 | |
| Current ratio | 1.66 | 1.59 | 1.87 | 1.73 | 1.51 | |
| Interest coverage | 0 | -15.72 | -11.43 | -9.08 | 10.11 | |
| Income quality | 22.17 | -1.55 | 0.16 | -4.26 | 3.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0.04 | 0.06 | 0.16 | |
| Capex to operating cash flow | -0.19 | 0.3 | -0.06 | 0.22 | 4.27 | |
| Capex to revenue | -0.02 | -0.03 | -1.21 | -0.78 | -4.97 | |
| Capex to depreciation | -0.27 | -0.28 | -0.17 | -0.08 | -0.84 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.17 | 0.67 | 2.64 | 1.29 | 2.17 | |
| ROIC | 0.02 | -0.1 | 0.15 | 0.02 | -0.08 | |
| Return on tangible assets | 0 | 0.01 | 0.1 | 0.02 | -0.06 | |
| Graham Net | -0.35 | -0.58 | -0.22 | -0.54 | -0.92 | |
| Working capital | 3.29M | 3.53M | 5.33M | 4.33M | 3.24M | |
| Tangible asset value | 0 | 0 | 6.18M | 6.38M | 3.73M | |
| Net current asset value | 3.13M | 3.41M | 1.41M | -612.37K | -2.83M | |
| Invested capital | 0 | 0.01 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 7.84M | 7.95M | 8.09M | |
| Average payables | 1.58M | 1.86M | 1.86M | 1.8M | 2.48M | |
| Average inventory | 620.5K | 746.62K | 828.21K | 590.21K | 666.37K | |
| Days sales outstanding | 0 | 0 | 141.61 | 147.33 | 186.73 | |
| Days payables outstanding | 76.4 | 101.75 | 460.38 | 233.95 | 1.26K | |
| Days of inventory on hand | 21.07 | 34.99 | 339.23 | 98 | 319.96 | |
| Receivables turnover | 0 | 0 | 0.64 | 0.61 | 0.48 | |
| Payables turnover | 1.18 | 0.88 | 0.2 | 0.38 | 0.07 | |
| Inventory turnover | 4.27 | 2.57 | 0.27 | 0.92 | 0.28 | |
| ROE | 0 | 0.03 | 0.23 | 0.04 | -0.15 | |
| Capex per share | -0.01 | -0.01 | -0.69 | -1.1 | -0.14 |
ALGEN.PA Frequently Asked Questions
What is genOway Société anonyme stock symbol ?
genOway Société anonyme is a FR stock , located in Lyon of Auvergne-rhone-alpes and trading under the symbol ALGEN.PA
What is genOway Société anonyme stock quote today ?
genOway Société anonyme stock price is $3.9 today.
Is genOway Société anonyme stock public?
Yes, genOway Société anonyme is a publicly traded company.
Company Profile
- Volume Average 7.07K
- Market Capitalization 33.27M
- Employee 128
- CEO Dr. Alexandre Fraichard
- Headquarters LYON,AUVERGNE-RHONE-ALPES,FR
- IPO Date 2007-05-04
-
Website
https://www.genoway.com 
genOway Société anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and immune checkpoint catalog cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was founded in 1999 and is headquartered in Lyon, France.
